title: Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2.
abstract: Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous group of disorders. A particularly severe subgroup first described in 1894, and subsequently called Brown-Vialetto-Van Laere syndrome, is characterized by progressive pontobulbar palsy, sensorineural hearing loss and respiratory insufficiency. There has been no treatment for this progressive neurodegenerative disorder, which leads to respiratory failure and usually death during childhood. We recently reported the identification of SLC52A2, encoding riboflavin transporter RFVT2, as a new causative gene for Brown-Vialetto-Van Laere syndrome. We used both exome and Sanger sequencing to identify SLC52A2 mutations in patients presenting with cranial neuropathies and sensorimotor neuropathy with or without respiratory insufficiency. We undertook clinical, neurophysiological and biochemical characterization of patients with mutations in SLC52A2, functionally analysed the most prevalent mutations and initiated a regimen of high-dose oral riboflavin. We identified 18 patients from 13 families with compound heterozygous or homozygous mutations in SLC52A2. Affected individuals share a core phenotype of rapidly progressive axonal sensorimotor neuropathy (manifesting with sensory ataxia, severe weakness of the upper limbs and axial muscles with distinctly preserved strength of the lower limbs), hearing loss, optic atrophy and respiratory insufficiency. We demonstrate that SLC52A2 mutations cause reduced riboflavin uptake and reduced riboflavin transporter protein expression, and we report the response to high-dose oral riboflavin therapy in patients with SLC52A2 mutations, including significant and sustained clinical and biochemical improvements in two patients and preliminary clinical response data in 13 patients with associated biochemical improvements in 10 patients. The clinical and biochemical responses of this SLC52A2-specific cohort suggest that riboflavin supplementation can ameliorate the progression of this neurodegenerative condition, particularly when initiated soon after the onset of symptoms.
authors.affiliation: 1 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK.
authors.forename: A Reghan
authors.initials: AR
authors.lastname: Foley
authors.forename: Manoj P
authors.initials: MP
authors.lastname: Menezes
authors.forename: Amelie
authors.initials: A
authors.lastname: Pandraud
authors.forename: Michael A
authors.initials: MA
authors.lastname: Gonzalez
authors.forename: Ahmad
authors.initials: A
authors.lastname: Al-Odaib
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Abrams
authors.forename: Kumiko
authors.initials: K
authors.lastname: Sugano
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yonezawa
authors.forename: Adnan Y
authors.initials: AY
authors.lastname: Manzur
authors.forename: Joshua
authors.initials: J
authors.lastname: Burns
authors.forename: Imelda
authors.initials: I
authors.lastname: Hughes
authors.forename: B Gary
authors.initials: BG
authors.lastname: McCullagh
authors.forename: Heinz
authors.initials: H
authors.lastname: Jungbluth
authors.forename: Ming J
authors.initials: MJ
authors.lastname: Lim
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Lin
authors.forename: Andre
authors.initials: A
authors.lastname: Megarbane
authors.forename: J Andoni
authors.initials: JA
authors.lastname: Urtizberea
authors.forename: Ayaz H
authors.initials: AH
authors.lastname: Shah
authors.forename: Jayne
authors.initials: J
authors.lastname: Antony
authors.forename: Richard
authors.initials: R
authors.lastname: Webster
authors.forename: Alexander
authors.initials: A
authors.lastname: Broomfield
authors.forename: Joanne
authors.initials: J
authors.lastname: Ng
authors.forename: Ann A
authors.initials: AA
authors.lastname: Mathew
authors.forename: James J
authors.initials: JJ
authors.lastname: O'Byrne
authors.forename: Eva
authors.initials: E
authors.lastname: Forman
authors.forename: Mariacristina
authors.initials: M
authors.lastname: Scoto
authors.forename: Manish
authors.initials: M
authors.lastname: Prasad
authors.forename: Katherine
authors.initials: K
authors.lastname: O'Brien
authors.forename: Simon
authors.initials: S
authors.lastname: Olpin
authors.forename: Marcus
authors.initials: M
authors.lastname: Oppenheim
authors.forename: Iain
authors.initials: I
authors.lastname: Hargreaves
authors.forename: John M
authors.initials: JM
authors.lastname: Land
authors.forename: Min X
authors.initials: MX
authors.lastname: Wang
authors.forename: Kevin
authors.initials: K
authors.lastname: Carpenter
authors.forename: Rita
authors.initials: R
authors.lastname: Horvath
authors.forename: Volker
authors.initials: V
authors.lastname: Straub
authors.forename: Monkol
authors.initials: M
authors.lastname: Lek
authors.forename: Wendy
authors.initials: W
authors.lastname: Gold
authors.forename: Michael O
authors.initials: MO
authors.lastname: Farrell
authors.forename: Sebastian
authors.initials: S
authors.lastname: Brandner
authors.forename: Rahul
authors.initials: R
authors.lastname: Phadke
authors.forename: Kazuo
authors.initials: K
authors.lastname: Matsubara
authors.forename: Michael L
authors.initials: ML
authors.lastname: McGarvey
authors.forename: Steven S
authors.initials: SS
authors.lastname: Scherer
authors.forename: Peter S
authors.initials: PS
authors.lastname: Baxter
authors.forename: Mary D
authors.initials: MD
authors.lastname: King
authors.forename: Peter
authors.initials: P
authors.lastname: Clayton
authors.forename: Shamima
authors.initials: S
authors.lastname: Rahman
authors.forename: Mary M
authors.initials: MM
authors.lastname: Reilly
authors.forename: Robert A
authors.initials: RA
authors.lastname: Ouvrier
authors.forename: John
authors.initials: J
authors.lastname: Christodoulou
authors.forename: Stephan
authors.initials: S
authors.lastname: Züchner
authors.forename: Francesco
authors.initials: F
authors.lastname: Muntoni
authors.forename: Henry
authors.initials: H
authors.lastname: Houlden
mesh_terms: D000293:Adolescent; D001921:Brain / Q000473:pathology; D010244:Bulbar Palsy, Progressive / Q000188:drug therapy / Q000235:genetics*; D002331:Carnitine / Q000031:analogs & derivatives / Q000097:blood; D002648:Child; D002675:Child, Preschool; D059472:Exome / Q000235:genetics; D005260:Female; D005838:Genotype; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D046228:Microarray Analysis; D016472:Motor Neuron Disease / Q000503:physiopathology; D009154:Mutation / Q000235:genetics*; D009460:Neurologic Examination; D010375:Pedigree; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D043562:Receptors, G-Protein-Coupled / Q000235:genetics*; D012256:Riboflavin / Q000627:therapeutic use; D017422:Sequence Analysis, DNA; D013497:Sural Nerve / Q000473:pathology; D014815:Vitamins / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D043562:Receptors, G-Protein-Coupled; C540350:SLC52A2 protein, human; D014815:Vitamins; C116917:acylcarnitine; D012313:RNA; D002331:Carnitine; D012256:Riboflavin
keywords: Brown-Vialetto-Van Laere syndrome; RFVT2; SLC52A2; childhood neuronopathy; riboflavin therapy